Positionsbestimmung zum Stellenwert von Pioglitazon in der Diabetestherapie

S. Eckert; E. Erdmann; R. Lundershausen; T. Forst; W. A. Scherbaum; O. Schnell; E. Standl; P.-M. Schumm-Draeger; D. Tschöpe; H. Walter; M. Weber

doi:10.1055/s-2007-993115

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2007; 132(49): 2650-2653
DOI: 10.1055/s-2007-993115

Konsensus | Review article

Kardiologie, Diabetologie
© Georg Thieme Verlag KG Stuttgart · New York

Positionsbestimmung zum Stellenwert von Pioglitazon in der Diabetestherapie

Significance of pioglitazone in the therapy of diabetes: determining the current positionS. Eckert¹ , E. Erdmann² , R. Lundershausen³ , T. Forst⁴ , W. A. Scherbaum⁵ , O. Schnell⁶ , E. Standl⁶ , P-M. Schumm-Draeger⁷ , D. Tschöpe⁸ , H. Walter⁹ , M. Weber¹⁰

¹Klinik für Kardiologie, Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen
²Klinik III für Innere Medizin, Klinikum der Universität zu Köln
³Bundesverband Deutscher Diabetologen e. V., Potsdam
⁴ Institut für klinische Forschung und Entwicklung, Mainz
⁵Klinik für Endokrinologie, Diabetologie und Rheumatologie der Universität Düsseldorf
⁶Institut für Diabetesforschung, München
⁷III. Medizinische Abteilung, Klinikum München-Bogenhausen
⁸Diabetesklinik, Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen
⁹Medizinische Klinik IV, Städtisches Klinikum Nürnberg
¹⁰Schwerpunkt Endokrinologie und Diabetologie, I. Medizinische Klinik und Poliklinik der Universität Mainz

Abstract

Schlüsselwörter

Diabetes mellitus Typ 2 - Glitazone - kardiovaskuläres Risiko - Pioglitazon - Rosiglitazon

Key words

type 2 diabetes mellitus - pioglitazone - rosiglitazone - cardiovascular risk - thiazolidinediones

Full Text

References

Literatur

1 Ahmed W, Ziouzenkova O, Brown J. et al . PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?. J Intern Med. 2007; 262 (2) 184-198
2 Berhanu P, Kipnes M S, Khan M A. et al . Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diab Vasc Dis Res. 2006; 3 (1) 39-44
3 Chappuis B, Braun M, Stettler C. et al . Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab Res Rev. 2007; 23 (5) 392-399
4 Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med. 2004; 164 (19) 2097-2104
5 Deeg M A, Buse J B, Goldberg R B. et al . Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2007; 30 (10) 2458-2464
6 Derosa G, D’Angelo A, Ragonesi P D. et al . Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther. 2006; 31 (4) 375-383
7 Dormandy J A, Charbonnel B, Eckland D J. et al . Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366 (9493) 1279-1289
8 Erdmann E, Charbonnel B, Wilcox R G. et al . Pioglitazone Use and Heart Failure in Patients with Type 2 Diabetes and Preexisting Cardiovascular Disease: Data from the PROactive Study (PROactive 08). Diabetes Care. 2007; 30 (11) 2773-2778
9 Erdmann E, Dormandy J A, Charbonnel B. et al . The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 2007; 49 (17) 1772-1780
10 Erdmann E, Schneider C A, Yates J. Effects of pioglitazone in patients with type 2 diabetes and reduced glomerular filtration rate: an analysis from PROactive. Diabetes. 2007; 56 (Suppl 1) A 178
11 European Medicines Agency confirms positive benefit-risk balance for rosiglitazone and pioglitazone. http://www.emea.europa.eu/pdfs/human/press/pr/48427707en.pdf
12 Fachinformation actos®. Stand August 2007
13 Fachinformation Avandia®. Stand Januar 2007
14 Forst T, Pfützner A, Lübben G. et al . Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk-the PIOSTAT Study. Metabolism. 2007; 56 (4) 491-496
15 GlaxoSmithKline (GSK) .Clinical trial observation of an increased incidence of fractures in female patients who received long-term treatment with Avandia (rosiglitazone maleate) tablets for type 2 diabetes mellitus (Letter to Health Care Providers). February 2007 Available from www.fda.gov/MedWatch/safety/2007/Avandia_GSK_Ltr.pdf
16 Goldberg R B, Kendall D M, Deeg M A. et al . A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005; 28 (7) 1547-1554
17 Goodman S B, Jiranek W, Petrow E, Yasko A W. The effects of medications on bone. J Am Acad Orthop Surg. 2007; 15 (8) 450-460
18 Home P D, Pocock S J, Beck-Nielsen H. et al . Rosiglitazone evaluated for cardiovascular outcomes. N Engl J Med. 2007; 357 (1) 28-38
19 Hsiao A, Worrall D S, Olefsky J M, Subramaniam S. Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes. Bioinformatics. 2004; 20 (17) 3108-3127
20 Kahn S E, Haffner S M, Heise M A. et al . Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355 (23) 2427-2443
21 Krauss R M. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004; 27 (6) 1496-1504
22 Lago R M, Singh P P, Nesto R W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007; 370 (9593) 1129-1136
23 Lincoff A M, Wolski K, Nicholls S J, Nissen S E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007; 298 (10) 1180-1188
24 Mele K D. Avandia® (rosiglitazone maleate) GlaxoSmithKline NDA 21 - 071 Supplement 022 FDA META-ANALYSIS. http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4308s1-00-index.htm
25 Nissen S E, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356 (24) 2457-2471
26 Reynolds K, Goldberg R B. Thiazolidinediones: beyond glycemic control. Treat Endocrinol. 2006; 5 (1) 25-36
27 Singh S, Loke Y K, Furberg C D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007; 298 (10) 1189-1195
28 Wilcox R, Bousser M G, Betteridge D J. et al . Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007; 38 (3) 865-873
29 Yang Y X, Lewis J D, Epstein S, Metz D C. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006; 296 2947-2953
30 FDA Adds Boxed Warning for Heart-related Risks to Anti-Diabetes Drug Avandia. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01743.html

Prof. Dr. Erland Erdmann

Klinikum der Universität zu Köln, Klinik III für Innere Medizin

Kerpener Str. 62

50924 Köln

Email: erland.erdmann@uni-koeln.de